- Recommendation ID
- TA310/1
- Question
- NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine kinase inhibitors (afatinib, erlotinib and gefitinib) in EGFR mutation-positive locally advanced or metastatic NSCLC.
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
- Number
- TA310
- Date issued
- April 2014
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 23/05/2014 |